China Medical System (867.HK) Collaborated with Trinomab in Regard to the Second Innovative Product
2021-06-21 19:43

On 21 June 2021, China Medical System Holdings Limited (¡°CMS¡±, together with its subsidiaries, the ¡°Group¡±) entered into a supplementary agreement with the innovative biotech company Trinomab Biotech Co., Ltd. (¡°Trinomab¡±). Trinomab will contribute the related technologies of the second innovative product --- Fully Human Anti-human Cytomegalovirus Monoclonal Antibody regarding its rights and interests in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan as intangible assets to the joint venture that will be established by the Group and Trinomab. The collaboration will further enrich the Group's innovative drug portfolio and reinforce the Group's innovative capabilities.

In April this year, the Group announced that it would make equity investment in and establish a joint venture with Trinomab, which initiated a new model for the Group¡¯s industrial investment in innovative biotech companies. Trinomab's natural fully human monoclonal antibody R&D integrated technology platform and the Group's capabilities in clinical development and commercialization will complement each other, enabling the strategic alliance of innovation and commercialization capabilities, and accelerating the process from discovery and clinical development, to commercialization of innovative drugs.

Fully Human Anti- human Cytomegalovirus Monoclonal Antibody

Fully Human Anti-human Cytomegalovirus (HCMV) Monoclonal Antibody  is developed via Trinomab¡¯s platform HitmAb® and currently in the preclinical stage. The greatest feature of the natural fully human monoclonal antibodies developed by HitmAb® is its high safety, having broad spectrum to foreign pathogens and strong affinity with pathogen targets, which can solve the problem of anti-drug antibody reaction in the clinical use of antibody drugs developed by traditional technologies.

HCMV infection is prevalent in the human population. Domestic research shows the seropositive rate of HCMV in Chinese adults is more than 97%. HCMV infection can cause severe pathological damage in people with low immunity, such as newborns and organ transplant recipients. Currently, there is no HCMV vaccine launched in the world. Only a few antiviral drugs have been approved for the treatment of HCMV infection. With just a single target, moderate antiviral activity, and poor bioavailability, these drugs are easy to be resistant to or cause severe adverse reactions. Besides, blood products such as intravenous immunoglobulin (IVIG) and HCMV-specific immunoglobulin (IgG, not launched in China) are approved for adjuvant prevention of HCMV in some organ transplant recipients. The users of these blood products is restricted and with low accessibility.

Fully human anti-HCMV monoclonal antibody has a precise mechanism of action and excellent safety. Due to its Non-blood-derived production process, it can be produced on a large scale under strict quality control, which can improve drug accessibility. Once launched in the future, the product is expected to fill the gap of HCMV monoclonal antibodies in the world,  bringing an effective and safe preventative therapy to patients.

In addition to the two collaborative products, the Group will further negotiate with Trinomab to promote the priority collaboration between the two parties on other specific products, so as to promote the launch of natural full-human monoclonal antibody drugs with good efficacy and safety in China, to benefit more patients.